BioAtla licenses Nectin-4 x CD3 bispecific antibody to Context Therapeutics for up to $133.5M

BioAtla, Inc.

BioAtla grants exclusive worldwide license to Context for two antibodies including BA3362 (CT-202), a Nectin-4 x CD3 TCE bispecific.
BioAtla eligible for up to $133.5M total, including $15M upfront/near-term milestones and $118.5M in future milestones plus tiered royalties.
BioAtla enters Global Transaction Agreement with Himalaya Therapeutics, consenting to license and sharing a mid-teens percentage of upfront/milestone payments.
Context may terminate at will; BioAtla may terminate if Context halts development for 8 consecutive quarters.
BioAtla agrees to refrain from competitive activities regarding Nectin-4 bispecific/multi-specific antibodies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.